Pharmaron Beijing Co., Ltd. Share Price
Equities
300759
CNE100003JW4
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.37 CNY | +4.42% |
|
+5.46% | -0.21% |
| Capitalization | 4.82TCr 701.01Cr 608.12Cr 549.84Cr 525Cr 954.92Cr 65TCr 988.35Cr 6.54TCr 2.6TCr 31TCr 2.63TCr 2.57TCr 1,11600Cr | P/E ratio 2025 * |
28.9x | P/E ratio 2026 * | 23.7x |
|---|---|---|---|---|---|
| Enterprise value | 5.11TCr 743.81Cr 645.25Cr 583.41Cr 557.05Cr 1.01TCr 69TCr 1.05TCr 6.94TCr 2.76TCr 33TCr 2.79TCr 2.73TCr 1,18400Cr | EV / Sales 2025 * |
3.64x | EV / Sales 2026 * | 3.11x |
| Free-Float |
48.56% | Yield 2025 * |
0.71% | Yield 2026 * | 0.87% |
| 1 day | +4.42% | ||
| 1 week | +5.46% | ||
| Current month | -4.16% | ||
| 1 month | -7.68% | ||
| 3 months | -5.15% | ||
| 6 months | -15.94% | ||
| Current year | -0.21% |
| 1 week | 26.49 |  | 29.64 |
| 1 month | 26.49 | | 30.48 |
| Current year | 26.49 | | 34.55 |
| 1 year | 20.47 | | 37.63 |
| 3 years | 17.7 | | 40.43 |
| 5 years | 17.7 | | 108.71 |
| 10 years | 4.08 | | 108.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
PSD | President | 57 | - |
Bei Zheng
PRN | Corporate Officer/Principal | 59 | 27/10/2016 |
Bo Liang Lou
CEO | Chief Executive Officer | 62 | 27/10/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Liang Lou
CHM | Chairman | 62 | 27/10/2016 |
Bei Zheng
BRD | Director/Board Member | 59 | 27/10/2016 |
Ke Xin Yang
CHM | Chairman | 64 | 27/10/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.42% | +5.46% | +5.82% | -25.62% | 701.01Cr | |
| -0.45% | -4.28% | -10.73% | -8.25% | 4.34TCr | |
| -4.55% | -2.61% | +14.19% | +31.94% | 3.16TCr | |
| -1.44% | -2.60% | +14.63% | +45.41% | 3.03TCr | |
| -5.04% | -8.72% | -12.13% | -17.40% | 2.74TCr | |
| -4.54% | -4.59% | +142.53% | +357.95% | 1.88TCr | |
| +0.66% | -3.51% | +52.36% | +115.62% | 1.41TCr | |
| -7.09% | -5.44% | +36.61% | +153.01% | 1.26TCr | |
| -1.36% | -5.79% | +20.71% | -3.55% | 1.25TCr | |
| -3.28% | -3.75% | +116.52% | +113.02% | 1.19TCr | |
| Average | -2.26% | -3.99% | +38.05% | +76.21% | 2.1TCr | |
| Weighted average by Cap. | -2.56% | -4.61% | +27.05% | +61.90% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.4TCr 204.52Cr 177.42Cr 160.41Cr 153.17Cr 278.6Cr 19TCr 288.35Cr 1.91TCr 758.06Cr 9.02TCr 767.47Cr 751.11Cr 33TCr | 1.62TCr 236.22Cr 204.92Cr 185.28Cr 176.91Cr 321.78Cr 22TCr 333.05Cr 2.21TCr 875.57Cr 10TCr 886.44Cr 867.54Cr 38TCr |
| Net income | 173.99Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.34TCr 36Cr 236.46Cr 94Cr 1.12TCr 95Cr 93Cr 4.03TCr | 215.21Cr 31Cr 27Cr 25Cr 23Cr 43Cr 2.89TCr 44Cr 292.47Cr 116.13Cr 1.38TCr 117.57Cr 115.06Cr 4.99TCr |
| Net Debt | 293.98Cr 43Cr 37Cr 34Cr 32Cr 58Cr 3.95TCr 60Cr 399.52Cr 158.64Cr 1.89TCr 160.61Cr 157.19Cr 6.81TCr | 223.44Cr 33Cr 28Cr 26Cr 24Cr 44Cr 3TCr 46Cr 303.66Cr 120.57Cr 1.44TCr 122.07Cr 119.47Cr 5.18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 28.37 ¥ | +4.42% | 5,80,48,620 |
| 11/26/11 | 27.17 ¥ | -1.24% | 1,55,90,570 |
| 10/26/10 | 27.51 ¥ | +1.48% | 1,66,98,830 |
| 09/26/09 | 27.11 ¥ | -0.88% | 1,67,80,050 |
| 06/26/06 | 27.35 ¥ | +1.67% | 1,60,64,850 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300759 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition